From the Faculté de Médecine (M.-Ê.P.).
NeuroPoly Lab, Institute of Biomedical Engineering, Polytechnique Montreal (M.-Ê.P., C.G., S.M.D., J.C.-A.), Montreal, Quebec, Canada.
AJNR Am J Neuroradiol. 2018 Jan;39(1):184-192. doi: 10.3174/ajnr.A5427. Epub 2017 Nov 9.
BACKGROUND AND PURPOSE: There is an emerging need for biomarkers to better categorize clinical phenotypes and predict progression in amyotrophic lateral sclerosis. This study aimed to quantify cervical spinal gray matter atrophy in amyotrophic lateral sclerosis and investigate its association with clinical disability at baseline and after 1 year. MATERIALS AND METHODS: Twenty-nine patients with amyotrophic lateral sclerosis and 22 healthy controls were scanned with 3T MR imaging. Standard functional scale was recorded at the time of MR imaging and after 1 year. MR imaging data were processed automatically to measure the spinal cord, gray matter, and white matter cross-sectional areas. A statistical analysis assessed the difference in cross-sectional areas between patients with amyotrophic lateral sclerosis and controls, correlations between spinal cord and gray matter atrophy to clinical disability at baseline and at 1 year, and prediction of clinical disability at 1 year. RESULTS: Gray matter atrophy was more sensitive to discriminate patients with amyotrophic lateral sclerosis from controls ( = .004) compared with spinal cord atrophy ( = .02). Gray matter and spinal cord cross-sectional areas showed good correlations with clinical scores at baseline ( = 0.56 for gray matter and = 0.55 for spinal cord; < .01). Prediction at 1 year with clinical scores ( = 0.54) was improved when including a combination of gray matter and white matter cross-sectional areas ( = 0.74). CONCLUSIONS: Although improvements over spinal cord cross-sectional areas were modest, this study suggests the potential use of gray matter cross-sectional areas as an MR imaging structural biomarker to monitor the evolution of amyotrophic lateral sclerosis.
背景与目的:目前需要生物标志物来更好地对临床表型进行分类,并预测肌萎缩侧索硬化症的进展。本研究旨在定量测量肌萎缩侧索硬化症患者的颈椎脊髓灰质萎缩,并探讨其与基线时和 1 年后临床残疾的相关性。
材料与方法:29 例肌萎缩侧索硬化症患者和 22 名健康对照者接受了 3T MRI 扫描。在 MRI 检查时和 1 年后记录了标准功能量表。MR 成像数据经过自动处理,以测量脊髓、灰质和白质的横截面积。统计分析评估了肌萎缩侧索硬化症患者与对照组之间的横截面积差异、脊髓和灰质萎缩与基线和 1 年后临床残疾的相关性,以及对 1 年后临床残疾的预测。
结果:与脊髓萎缩相比,灰质萎缩更能敏感地区分肌萎缩侧索硬化症患者与对照组( =.004)。灰质和脊髓的横截面积与基线时的临床评分具有良好的相关性(灰质为 = 0.56,脊髓为 = 0.55;均<.01)。将灰质和白质的横截面积组合后,对 1 年后的临床评分预测能力得到了提高( = 0.74)。
结论:尽管与脊髓横截面积相比,改善幅度较小,但本研究表明,灰质横截面积可能作为 MRI 结构生物标志物,用于监测肌萎缩侧索硬化症的演变。
AJNR Am J Neuroradiol. 2017-11-9
Ann Clin Transl Neurol. 2023-2
J Magn Reson Imaging. 2017-6-7
Imaging Neurosci (Camb). 2024-2-2
Neuroimage Clin. 2025-6-26
Neuroimage Clin. 2016-10-11
PLoS One. 2016-4-18
Curr Neurol Neurosci Rep. 2015-7
Nat Rev Neurol. 2014-10-14
Muscle Nerve. 2015-1